Actinin-4 expression in ovarian cancer: A novel prognostic indicator independent of clinical stage and histological type

Modern Pathology

Volumn 20, Issue 12, 2007, Pages 1278-1285

  Yamamoto, Sohei ^a   Tsuda, Hitoshi ^a,b   Honda, Kazufumi ^c   Kita, Tsunekazu ^a   Takano, Masashi ^a   Tamai, Seiichi ^a   Inazawa, Johji ^b,d   Yamada, Tesshi ^c   Matsubara, Osamu ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Actinin 4; Cell adhesion; Cell motility; Ovarian cancer; Prognostic factor

Indexed keywords

ACTININ; BETA CATENIN; UVOMORULIN;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL MOTILITY; CLEAR CELL CARCINOMA; CYTOPLASM; ENDOMETRIOID CARCINOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOG RANK TEST; MAJOR CLINICAL STUDY; METASTASIS; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ACTININ; BETA CATENIN; CADHERINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 36249031994     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800966     Document Type: Article

References (38)

1. Kumar V, Abbas AK, Fausto N (eds). Neoplasia. In: Robbins and Cotran. Pathologic Basis of Disease, 7th edn. Elsevier Saunders: PA, USA, 2004, pp 269-342.
2. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990;322:605-612.
3. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, et al. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-1383.
4. Partin AW, Schoeniger JS, Mohler JL, et al. Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci USA 1989;86:1254-1258.
5. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996;84:359-369.
6. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31-101.
7. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-357.
8. Pantaloni D, Le Clainche C, Carlier MF. Mechanism of actin-based motility. Science 2001;292:1502-1506.
9. Honda K, Yamada T, Endo R, et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 1998;23:1383-1393.
10. Honda K, Yamada T, Hayashida Y, et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005;128:51-62.
11. Araki N, Hatae T, Yamada T, et al. Actinin-4 is preferentially involved in circular ruffling and macropinocytosis in mouse macrophages: analysis by fluorescence ratio imaging. J Cell Sci 2000;113:3329-3340.
12. Gonzalez AM, Otey C, Edlund M, et al. Interactions of a hemidesmosome component and actinin family members. J Cell Sci 2001;114:4197-4206.
13. Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003;9:4695-4704.
14. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ (eds). Blaustein's Pathology of the Female Genital Tract, 5th edn. Springer-Verlag: New York, 2001, pp 791-904.
15. Risinger JI, Berchuck A, Kohler MF, et al. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994;7:98-102.
16. Imai T, Horiuchi A, Shiozawa T, et al. Elevated expression of E-cadherin and alpha-, beta-, gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 2004;35:1469-1476.
17. Voutilainen KA, Anttila MA, Sillanpaa SM, et al. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 2006;59:460-467.
18. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 2004;35:663-669.
19. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 2004;15:1535-1542.
20. Bankfalvi A, Krassort M, Buchwalow IB, et al. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol 2002;198:343-351.
21. Huiping C, Kristjansdottir S, Jonasson JG, et al. Alterations of E-cadherin and beta-catenin in gastric cancer. BMC Cancer 2001;1:16-25.
22. Krishnadath KK, Tilanus HW, van Blankenstein M, et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997;182:331-338.
23. Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000;6:4789-4796.
24. Yoshida R, Kimura N, Harada Y, et al. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001;18:513-520.
25. Tavassoli FA, Devilee P, (eds). World Health Organization classification of tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003, pp 218-228.
26. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
27. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
29. Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000;24:251-256.
30. Youssoufian H, McAfee M, Kwiatkowski DJ. Cloning and chromosomal localization of the human cytoskeletal alpha-actinin gene reveals linkage to the beta-spectrin gene. Am J Hum Genet 1990;47:62-72.
31. Otey CA, Vasquez GB, Burridge K, et al. Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. J Biol Chem 1993;268:21193-21197.
32. Knudsen KA, Soler AP, Johnson KR, et al. Interaction of alpha-actinin with the cadherin/catenin cell-cell adhesion complex via alpha-catenin. J Cell Biol 1995;130:67-77.
33. Raffioni S, Bradshaw RA. Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells. Proc Natl Acad Sci USA 1992;89:9121-9125.
34. Roche S, Downward J, Raynal P, et al. A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction. Mol Cell Biol 1998;18:7119-7129.
35. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-1606.
36. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
37. Hu L, Zaloudek C, Mills GB, et al. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880-886.
38. Hayashida Y, Honda K, Idogawa M, et al. E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res 2005;65:8836-8845.